U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H24N2O2.ClH
Molecular Weight 300.824
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TETRACAINE HYDROCHLORIDE

SMILES

Cl.CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C

InChI

InChIKey=PPWHTZKZQNXVAE-UHFFFAOYSA-N
InChI=1S/C15H24N2O2.ClH/c1-4-5-10-16-14-8-6-13(7-9-14)15(18)19-12-11-17(2)3;/h6-9,16H,4-5,10-12H2,1-3H3;1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C15H24N2O2
Molecular Weight 264.3633
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: https://en.wikipedia.org/wiki/Tetracaine http://www.medchemexpress.com/Tetracaine.html

Tetracaine (INN, also known as amethocaine; trade name Pontocaine. Ametop and Dicaine) is a potent local anesthetic of the ester group. It is mainly used topically in ophthalmology and as an antipruritic, and it has been used in spinal anesthesia. Tetracaine blocks sodium ion channels required for the initiation and conduction of neuronal impulses thereby affecting local anesthesia. In biomedical research, tetracaine is used to alter the function of calcium release channels (ryanodine receptors) that control the release of calcium from intracellular stores. Tetracaine is an allosteric blocker of channel function. At low concentrations, tetracaine causes an initial inhibition of spontaneous calcium release events, while at high concentrations, tetracaine blocks release completely.

Originator

Curator's Comment: Tetracaine was first synthesized in Germany in 1928 by Otto Eisleb (1887-1948), a chemist working for IG Farben

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TETRACAINE HYDROCHLORIDE

Approved Use

is indicated for procedures requiring a rapid and shortacting topical ophthalmic anesthetic

Launch Date

2006
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.24 ng/mL
18 mg single, nasal
dose: 18 mg
route of administration: Nasal
experiment type: SINGLE
co-administered: OXYMETAZOLINE
TETRACAINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1.15 ng/mL
36 mg single, nasal
dose: 36 mg
route of administration: Nasal
experiment type: SINGLE
co-administered: OXYMETAZOLINE
TETRACAINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
492 ng/mL
18 mg single, nasal
dose: 18 mg
route of administration: Nasal
experiment type: SINGLE
co-administered: OXYMETAZOLINE
4-(BUTYLAMINO)BENZOIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
886 ng/mL
36 mg single, nasal
dose: 36 mg
route of administration: Nasal
experiment type: SINGLE
co-administered: OXYMETAZOLINE
4-(BUTYLAMINO)BENZOIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
862 ng × h/mL
18 mg single, nasal
dose: 18 mg
route of administration: Nasal
experiment type: SINGLE
co-administered: OXYMETAZOLINE
4-(BUTYLAMINO)BENZOIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1773 ng × h/mL
36 mg single, nasal
dose: 36 mg
route of administration: Nasal
experiment type: SINGLE
co-administered: OXYMETAZOLINE
4-(BUTYLAMINO)BENZOIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1 h
18 mg single, nasal
dose: 18 mg
route of administration: Nasal
experiment type: SINGLE
co-administered: OXYMETAZOLINE
4-(BUTYLAMINO)BENZOIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1.01 h
36 mg single, nasal
dose: 36 mg
route of administration: Nasal
experiment type: SINGLE
co-administered: OXYMETAZOLINE
4-(BUTYLAMINO)BENZOIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.5 % multiple, oromucosal
Dose: 0.5 %
Route: oromucosal
Route: multiple
Dose: 0.5 %
Sources:
unhealthy, 75 years
Health Status: unhealthy
Age Group: 75 years
Sex: M
Sources:
Other AEs: Toxic reaction (NOS)...
Other AEs:
Toxic reaction (NOS) (grade 5)
Sources:
AEs

AEs

AESignificanceDosePopulation
Toxic reaction (NOS) grade 5
0.5 % multiple, oromucosal
Dose: 0.5 %
Route: oromucosal
Route: multiple
Dose: 0.5 %
Sources:
unhealthy, 75 years
Health Status: unhealthy
Age Group: 75 years
Sex: M
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Tox targets
PubMed

PubMed

TitleDatePubMed
Calcium-induced calcium release and cyclic ADP-ribose-mediated signaling in the myocytes from small coronary arteries.
2002-09
Prophylactic IM small-dose phenylephrine blunts spinal anesthesia-induced hypotensive response during surgical repair of hip fracture in the elderly.
2002-09
Amphiphilic effects of local anesthetics on rotational mobility in neuronal and model membranes.
2002-08-19
Simultaneous determination of mepivacaine, tetracaine, and p-butylaminobenzoic acid by high-performance liquid chromatography.
2002-08-17
Managing patients with local anesthetic complications using alternative methods.
2002-08-15
Principles of office anesthesia: part II. Topical anesthesia.
2002-07-01
Allosterically linked noncompetitive antagonist binding sites in the resting nicotinic acetylcholine receptor ion channel.
2002-07-01
Ciguatoxin-induced oscillations in membrane potential and action potential firing in rat parasympathetic neurons.
2002-07
The inhibitory effect of local anesthetics on bradykinin-induced phospholipase D activation in rat pheochromocytoma PC12 cells.
2002-07
Assessment of sarcoplasmic reticulum Ca(2+) flux pathways in cardiomyocytes from rabbits with infarct-induced left-ventricular dysfunction.
2002-06
Interaction of monosulfonate tetraphenyl porphyrin, a competitive inhibitor, with acetylcholinesterase.
2002-06
Amethocaine-lidocaine cream, a new topical formulation for preventing venopuncture-induced pain in children.
2002-05-23
Agonist-induced phasic and tonic responses in smooth muscle are mediated by InsP(3).
2002-05-15
A laser-clinic nurse with allergic contact dermatitis from tetracaine.
2002-05
The effect of baricity of intrathecal morphine in children receiving tetracaine spinal anaesthesia for cardiac surgery: a preliminary report.
2002-05
Involvement of the mitogen-activated protein kinase family in tetracaine-induced PC12 cell death.
2002-05
Reagent-less detection of a competitive inhibitor of immobilized acetylcholinesterase.
2002-05
Tetramethylpyrazine attenuates spinal cord ischemic injury due to aortic cross-clamping in rabbits.
2002-04-17
Radial artery cannulation: topical amethocaine gel versus lidocaine infiltration.
2002-04
Lidocaine-prilocaine cream versus tetracaine gel for procedural pain in children.
2002-04
Buprenorphine added to the local anesthetic for axillary brachial plexus block prolongs postoperative analgesia.
2002-03-27
Bupivacaine, but not tetracaine, protects against the in vitro ischemic insult of rat hippocampal CA1 neurons.
2002-03
Topical anesthesia for minor gynecological procedures: a review.
2002-03
Spinal anesthesia in 62 premature, former-premature or young infants--technical aspects and pitfalls.
2002-03
A novel Ca2+-induced Ca2+ release mechanism mediated by neither inositol trisphosphate nor ryanodine receptors.
2002-02-01
Role of the dorsomedial striatum in behavioral flexibility for response and visual cue discrimination learning.
2002-02
Intercostal nerve block with 5% tetracaine for chronic pain syndromes.
2002-02
Lidocaine inhibits secretion of IL-8 and IL-1beta and stimulates secretion of IL-1 receptor antagonist by epithelial cells.
2002-02
The inhibition of the N-methyl-D-aspartate receptor channel by local anesthetics in mouse CA1 pyramidal neurons.
2002-02
Functional properties of ryanodine receptors from rat dorsal root ganglia.
2002-01-30
The feasibility of office-based laser-assisted tympanic membrane fenestration with tympanostomy tube insertion: the duPont Hospital experience.
2002-01-11
Distribution of tetracaine and its metabolite in rabbits after high versus normal spinal anesthesia.
2001-12-27
Spark- and ember-like elementary Ca2+ release events in skinned fibres of adult mammalian skeletal muscle.
2001-12-01
Topical anesthetics update: EMLA and beyond.
2001-12
Allergic contact dermatitis from local anaesthetic on peristomal skin.
2001-12
An integrative, in situ approach to examining K+ flux in resting skeletal muscle.
2001-12
[An electrophysiological study of ropivacaine on excised cervical vagus nerves of rabbit].
2001-12
Pharmacological regulation of gastric acid secretion in the apical membrane of parietal cells; a new target for antisecretory drugs.
2001-12
High-concentration tetracaine for the management of trigeminal neuralgia: quantitative assessment of sensory function after peripheral nerve block.
2001-12
Histamine-induced Ca2+ release in bovine adrenal chromaffin cells.
2001-12
Role of the bandage soft contact lens in the postoperative laser in situ keratomileusis patient.
2001-12
Inhibition of wild-type and mutant neuronal nicotinic acetylcholine receptors by local anesthetics.
2001-12
Local anesthetics noncompetitively inhibit function of four distinct nicotinic acetylcholine receptor subtypes.
2001-12
Ouabain stimulates unidirectional and net potassium efflux in resting mammalian skeletal muscle.
2001-11
Cauda equina syndrome after spinal tetracaine: electromyographic evaluation--20 years follow-up.
2001-11
[Low dose intrathecal morphine and postoperative pain relief in elderly patients].
2001-10
Spinal anesthesia in children: pro.
2001-09
Role of the dopamine transporter and the sodium channel in the cocaine-like discriminative stimulus effects of local anesthetics in rats.
2001-09
From cocaine to ropivacaine: the history of local anesthetic drugs.
2001-08
Topical anesthetics in children: agents and techniques that equally comfort patients, parents, and clinicians.
2001-08
Patents

Sample Use Guides

One drop topically in the eye(s)
Route of Administration: Topical
In Vitro Use Guide
Curator's Comment: The action of tetracaine hydrochloride in vitro on Pseudomonas aeruginosa was investigates. The inhibitory and bactericidal action of tetracaine hydrochloride in vitro was adversely affected by magnesium ions. Observation of cellular lysis, leakage of intracellular materials, dehydrogenase activity, and a higher sensitivity of spheroplasts than of whole cells to tetracaine led to the conclusion that tetracaine acts by damaging the cell membrane.
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:52:58 GMT 2025
Edited
by admin
on Mon Mar 31 17:52:58 GMT 2025
Record UNII
5NF5D4OPCI
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TETRACAINE HYDROCHLORIDE
EP   GREEN BOOK   MART.   MI   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
Common Name English
KOVANAZE COMPONENT TETRACAINE HYDROCHLORIDE
Preferred Name English
NSC-757337
Code English
MENONASAL
Common Name English
TETRACAINE HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
2-(DIMETHYLAMINO)ETHYL P-(BUTYLAMINO)BENZOATE MONOHYDROCHLORIDE
Common Name English
TETOCAINE
Common Name English
TETRACAINE HYDROCHLORIDE [MART.]
Common Name English
TETRACAINI HYDROCHLORIDUM [WHO-IP LATIN]
Common Name English
BUTETHANOL
Common Name English
TETRACAINE HYDROCHLORIDE [USP-RS]
Common Name English
PANTOCAINE
Common Name English
CURTACAIN
Common Name English
BENZOIC ACID, 4-(BUTYLAMINO)-, 2-(DIMETHYLAMINO)ETHYL ESTER, MONOHYDROCHLORIDE
Common Name English
DICAINUM [WHO-IP]
Common Name English
TETRACAINE HCL
Common Name English
TETRACAINE HYDROCHLORIDE [JAN]
Common Name English
TETRACA
Brand Name English
TETRACAINE HYDROCHLORIDE [GREEN BOOK]
Common Name English
TETRACAINE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
Tetracaine hydrochloride [WHO-DD]
Common Name English
TETRACAINE HYDROCHLORIDE [WHO-IP]
Common Name English
AMETHOCAINE HYDROCHLORIDE [WHO-IP]
Common Name English
TETRACAINE HYDROCHLORIDE [MI]
Common Name English
TETRACAINE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
ANETHAINE
Common Name English
TETRACAINE HYDROCHLORIDE [VANDF]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C245
Created by admin on Mon Mar 31 17:52:58 GMT 2025 , Edited by admin on Mon Mar 31 17:52:58 GMT 2025
CFR 21 CFR 310.527
Created by admin on Mon Mar 31 17:52:58 GMT 2025 , Edited by admin on Mon Mar 31 17:52:58 GMT 2025
CFR 21 CFR 346.10
Created by admin on Mon Mar 31 17:52:58 GMT 2025 , Edited by admin on Mon Mar 31 17:52:58 GMT 2025
EPA PESTICIDE CODE 97005
Created by admin on Mon Mar 31 17:52:58 GMT 2025 , Edited by admin on Mon Mar 31 17:52:58 GMT 2025
Code System Code Type Description
SMS_ID
100000091356
Created by admin on Mon Mar 31 17:52:58 GMT 2025 , Edited by admin on Mon Mar 31 17:52:58 GMT 2025
PRIMARY
EVMPD
SUB04754MIG
Created by admin on Mon Mar 31 17:52:58 GMT 2025 , Edited by admin on Mon Mar 31 17:52:58 GMT 2025
PRIMARY
CAS
136-47-0
Created by admin on Mon Mar 31 17:52:58 GMT 2025 , Edited by admin on Mon Mar 31 17:52:58 GMT 2025
PRIMARY
PUBCHEM
8695
Created by admin on Mon Mar 31 17:52:58 GMT 2025 , Edited by admin on Mon Mar 31 17:52:58 GMT 2025
PRIMARY
ChEMBL
CHEMBL698
Created by admin on Mon Mar 31 17:52:58 GMT 2025 , Edited by admin on Mon Mar 31 17:52:58 GMT 2025
PRIMARY
DAILYMED
5NF5D4OPCI
Created by admin on Mon Mar 31 17:52:58 GMT 2025 , Edited by admin on Mon Mar 31 17:52:58 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
TETRACAINE HYDROCHLORIDE
Created by admin on Mon Mar 31 17:52:58 GMT 2025 , Edited by admin on Mon Mar 31 17:52:58 GMT 2025
PRIMARY Description: A white, crystalline powder; odourless. Solubility: Soluble in about 8 parts of water; soluble in ethanol (~750 g/l) TS; practically insoluble in ether R. Category: Local anaesthetic. Storage: Tetracaine hydrochloride should be kept in a tightly closed container, protected from light. Additional information: Tetracaine hydrochloride is hygroscopic; it has a slightly bitter taste and causes local numbness afterbeing placed on the tongue. Even in the absence of light, it is gradually degraded on exposure to a humid atmosphere, thedecomposition being faster at higher temperatures. Tetracaine hydrochloride melts at about 148 ?C or may exist in either of the two polymorphic forms, one of which melts at 134 ?C and the other at 139 ?C. Mixtures of the forms melt within the range 134-147?C. Definition: Tetracaine hydrochloride contains not less than 98.0% and not more than 101.0% of C15H24N2O2,HCl, calculated with reference to the dried substance.
NCI_THESAURUS
C75104
Created by admin on Mon Mar 31 17:52:58 GMT 2025 , Edited by admin on Mon Mar 31 17:52:58 GMT 2025
PRIMARY
NSC
757337
Created by admin on Mon Mar 31 17:52:58 GMT 2025 , Edited by admin on Mon Mar 31 17:52:58 GMT 2025
PRIMARY
RS_ITEM_NUM
1650006
Created by admin on Mon Mar 31 17:52:58 GMT 2025 , Edited by admin on Mon Mar 31 17:52:58 GMT 2025
PRIMARY
ECHA (EC/EINECS)
205-248-5
Created by admin on Mon Mar 31 17:52:58 GMT 2025 , Edited by admin on Mon Mar 31 17:52:58 GMT 2025
PRIMARY
FDA UNII
5NF5D4OPCI
Created by admin on Mon Mar 31 17:52:58 GMT 2025 , Edited by admin on Mon Mar 31 17:52:58 GMT 2025
PRIMARY
MERCK INDEX
m10603
Created by admin on Mon Mar 31 17:52:58 GMT 2025 , Edited by admin on Mon Mar 31 17:52:58 GMT 2025
PRIMARY Merck Index
DRUG BANK
DBSALT001125
Created by admin on Mon Mar 31 17:52:58 GMT 2025 , Edited by admin on Mon Mar 31 17:52:58 GMT 2025
PRIMARY
EPA CompTox
DTXSID6042448
Created by admin on Mon Mar 31 17:52:58 GMT 2025 , Edited by admin on Mon Mar 31 17:52:58 GMT 2025
PRIMARY
RXCUI
91189
Created by admin on Mon Mar 31 17:52:58 GMT 2025 , Edited by admin on Mon Mar 31 17:52:58 GMT 2025
PRIMARY RxNorm
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
USP
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 0.7
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 0.6
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY